Drug Profile
Research programme: cytotoxic T lymphocytes - Multimeric Biotherapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Multimeric Biotherapeutics
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Oct 2011 Preclinical trials in Cancer in USA (Parenteral)